BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 19718038)

  • 1. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis.
    Zhao B; Takami M; Yamada A; Wang X; Koga T; Hu X; Tamura T; Ozato K; Choi Y; Ivashkiv LB; Takayanagi H; Kamijo R
    Nat Med; 2009 Sep; 15(9):1066-71. PubMed ID: 19718038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.
    Nakashima Y; Haneji T
    PLoS One; 2013; 8(9):e72033. PubMed ID: 24039733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DGKζ Downregulation Enhances Osteoclast Differentiation and Bone Resorption Activity Under Inflammatory Conditions.
    Iwazaki K; Tanaka T; Hozumi Y; Okada M; Tsuchiya R; Iseki K; Topham MK; Kawamae K; Takagi M; Goto K
    J Cell Physiol; 2017 Mar; 232(3):617-624. PubMed ID: 27312515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J.
    Zhao B; Grimes SN; Li S; Hu X; Ivashkiv LB
    J Exp Med; 2012 Feb; 209(2):319-34. PubMed ID: 22249448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling.
    AlQranei MS; Senbanjo LT; Aljohani H; Hamza T; Chellaiah MA
    BMC Immunol; 2021 Mar; 22(1):23. PubMed ID: 33765924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
    Rahman MM; Bhattacharya A; Fernandes G
    J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early estrogen-induced gene 1 facilitates osteoclast formation through the inhibition of interferon regulatory factor 8 expression.
    Jeong E; Kim J; Go M; Lee SY
    FASEB J; 2020 Sep; 34(9):12894-12906. PubMed ID: 32741026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
    Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).
    Chen Z; Su L; Xu Q; Katz J; Michalek SM; Fan M; Feng X; Zhang P
    J Biol Chem; 2015 Dec; 290(50):30163-74. PubMed ID: 26483549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L; Sapkota M; Kim SW; Soh Y
    Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
    Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
    J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
    Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
    Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Immunoglobulin (IVIG) Attenuates TNF-Induced Pathologic Bone Resorption and Suppresses Osteoclastogenesis by Inducing A20 Expression.
    Lee MJ; Lim E; Mun S; Bae S; Murata K; Ivashkiv LB; Park-Min KH
    J Cell Physiol; 2016 Feb; 231(2):449-458. PubMed ID: 26189496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.